Get the Stockscreener App
2.45
0.00%
0.00
Icecure Medical Ltd stock is traded at $2.45, with a volume of 33,075.
It is up +0.00% in the last 24 hours and down -27.08% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$2.45
Open:
$2.49
24h Volume:
33,075
Relative Volume:
0.01
Market Cap:
$8.40M
Revenue:
$3.57M
Net Income/Loss:
$-15.74M
P/E Ratio:
-0.3526
EPS:
-6.9481
Net Cash Flow:
$-15.77M
1W Performance:
-18.87%
1M Performance:
-27.08%
6M Performance:
-85.70%
1Y Performance:
-90.67%
1-Day Range:
$2.41
$2.49
1-Week Range:
$2.30
$3.05
52-Week Range:
$2.12
$42.00
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
2.45 | 8.64M | 3.57M | -15.74M | -15.77M | -6.9481 |
ABT
Abbott Laboratories
|
114.59 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.78 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.17 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.67 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.47 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd Stock (ICCM) Latest News
ICCM Looks 87.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study - Bitget
IceCure's ProSense Is First and Only for Low-Risk Breast Cancer With FDA Marketing Authorization - Stock Titan
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: R - GuruFocus
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript - AOL.ca
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - Vinanet
IceCure Medical Ltd. SEC Filing (Aug 19, 2026) - Stock Titan
IceCure Medical (ICCM) grants 131K RSUs to North America VP - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (NASDAQ: ICCM) director lists no shares - Stock Titan
IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs - Stock Titan
IceCure Medical (ICCM) awards COO 141K new RSUs - Stock Titan
IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake - Stock Titan
IceCure Medical (ICCM) director Chan Vincent leaves board - Stock Titan
ICCM Looks 85.8% Undervalued on GF Value™ - GuruFocus
IceCure Medical director David Salton files initial beneficial ownership statement - Bitget
IceCure Medical (ICCM) expands 2024 employee share incentive reserve - Stock Titan
Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control - Stock Titan
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
IceCure Medical (ICCM) Earnings Call zum 2. Quartal 2026: Umsatz im 1. Halbjahr steigt um 45 % - TradingKey
IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds - Stock Titan
New studies highlight FDA-approved ProSense cry... - pluang.com
Two papers examine tumor freezing beyond the primary breast tumor - Stock Titan
IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation - Bitget
IceCure Medical Q2 2026 Earnings Call Transcript - MarketBeat
IceCure Medical Ltd Q2 2026 Earnings Call Summary - Yahoo Finance
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year - GuruFocus
Earnings call transcript: IceCure Medical misses Q2 2026 estimates as shares fall - Investing.com
Icecure Medical Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
IceCure net loss widens to USD 8.78 million in H1 FY26; revenue rises 45% to USD 1.82 million - Bitget
IceCure Medical (Nasdaq: ICCM) lifts H1 revenue 45% but burns cash - Stock Titan
IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses - TradingKey
IceCure's Active U.S. Install Base Grows About 70%; Cash $12M - Stock Titan
IceCure Medical (ICCM) names David Salton to board as independent director - Stock Titan
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 (PR Newswire) - Aktiellt
Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside - GuruFocus
IceCure Medical Shareholders Approve Special Meeting Agenda on August 6, 2026 - The Globe and Mail
IceCure Medical (ICCM) holders approve agenda after adjourned meeting - Stock Titan
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment - Morningstar
IceCure Medical to Report First Half 2026 Financial and Operatin - GuruFocus
IceCure Medical Adds Adventist Health as U.S. Clinical Site for - GuruFocus
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026 - Finviz
IceCure Medical Will Discuss Six-Month Results on Aug. 12 - Stock Titan
Price to book forward of IceCure Medical Ltd. – NASDAQ:ICCM - TradingView
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense - Morningstar
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Ca - GuruFocus
IceCure Medical Kicks Off its Post-Marketing ChoICE Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site - marketscreener.com
Icecure Medical Ltd (ICCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Icecure Medical Ltd (ICCM) Institutional Confidence - TradingKey
Icecure Medical Ltd (ICCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IceCure Medical Kicks Off Post-Marketing ChoICE Study for ProSense Cryoablation in Low-Risk Breast Cancer Treatment at First U.S. Clinical Site - marketscreener.com
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):